Maarten P van den Berg1, Rowida Almomani2, Italo Biaggioni2, Martijn van Faassen2, Pim van der Harst2, Herman H W Silljé2, Irene Mateo Leach2, Marc H Hemmelder2, Gerjan Navis2, Gert Jan Luijckx2, Arjan P M de Brouwer2, Hanka Venselaar2, Marcel M Verbeek2, Paul A van der Zwaag2, Jan D H Jongbloed2, J Peter van Tintelen2, Ron A Wevers2, Ido P Kema2. 1. From the Department of Cardiology (M.P.v.d.B., P.v.d.H., H.H.W.S., I.M.L.), Laboratory Medicine (M.v.F., I.P.K.), Department of Nephrology (G.N.), Department of Neurology (G.J.L.), and Department of Genetics (P.A.v.d.Z., J.D.H.J.), University Medical Center Groningen, University of Groningen, The Netherlands; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid (R.A.); Division of Clinical Pharmacology, Vanderbilt University, Medical Center, Nashville, TN (I.B.); Department of Internal Medicine, Medical Center Leeuwarden, The Netherlands (M.H.H.); Department of Genetics (A.P.M.d.B.), Centre for Molecular and Biomolecular Informatics (H.V.), and Translational Metabolic Laboratory, Department of Laboratory Medicine (M.M.V., R.A.W.), Radboud University Medical Center Nijmegen, The Netherlands; and Department of Genetics, Academic Medical Center, University of Amsterdam, The Netherlands (J.P.v.T.). m.p.van.den.berg@umcg.nl. 2. From the Department of Cardiology (M.P.v.d.B., P.v.d.H., H.H.W.S., I.M.L.), Laboratory Medicine (M.v.F., I.P.K.), Department of Nephrology (G.N.), Department of Neurology (G.J.L.), and Department of Genetics (P.A.v.d.Z., J.D.H.J.), University Medical Center Groningen, University of Groningen, The Netherlands; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid (R.A.); Division of Clinical Pharmacology, Vanderbilt University, Medical Center, Nashville, TN (I.B.); Department of Internal Medicine, Medical Center Leeuwarden, The Netherlands (M.H.H.); Department of Genetics (A.P.M.d.B.), Centre for Molecular and Biomolecular Informatics (H.V.), and Translational Metabolic Laboratory, Department of Laboratory Medicine (M.M.V., R.A.W.), Radboud University Medical Center Nijmegen, The Netherlands; and Department of Genetics, Academic Medical Center, University of Amsterdam, The Netherlands (J.P.v.T.).
Abstract
RATIONALE: Orthostatic hypotension is a common clinical problem, but the underlying mechanisms have not been fully delineated. OBJECTIVE: We describe 2 families, with 4 patients in total, experiencing severe life-threatening orthostatic hypotension because of a novel cause. METHODS AND RESULTS: As in dopamine β-hydroxylase deficiency, concentrations of norepinephrine and epinephrine in the patients were low. Plasma dopamine β-hydroxylase activity, however, was normal, and the DBH gene had no mutations. Molecular genetic analysis was performed to determine the underlying genetic cause. Homozygosity mapping and exome and Sanger sequencing revealed pathogenic homozygous mutations in the gene encoding cytochrome b561 (CYB561); a missense variant c.262G>A, p.Gly88Arg in exon 3 in the Dutch family and a nonsense mutation (c.131G>A, p.Trp44*) in exon 2 in the American family. Expression of CYB561 was investigated using RNA from different human adult and fetal tissues, transcription of RNA into cDNA, and real-time quantitative polymerase chain reaction. The CYB561 gene was found to be expressed in many human tissues, in particular the brain. The CYB561 protein defect leads to a shortage of ascorbate inside the catecholamine secretory vesicles leading to a functional dopamine β-hydroxylase deficiency. The concentration of the catecholamines and downstream metabolites was measured in brain and adrenal tissue of 6 CYB561 knockout mice (reporter-tagged deletion allele [post-Cre], genetic background C57BL/6NTac). The concentration of norepinephrine and normetanephrine was decreased in whole-brain homogenates of the CYB561(-/-) mice compared with wild-type mice (P<0.01), and the concentration of normetanephrine and metanephrine was decreased in adrenal glands (P<0.01), recapitulating the clinical phenotype. The patients responded favorably to treatment with l-dihydroxyphenylserine, which can be converted directly to norepinephrine. CONCLUSIONS: This study is the first to implicate cytochrome b561 in disease by showing that pathogenic mutations in CYB561 cause an as yet unknown disease in neurotransmitter metabolism causing orthostatic hypotension.
RATIONALE: Orthostatic hypotension is a common clinical problem, but the underlying mechanisms have not been fully delineated. OBJECTIVE: We describe 2 families, with 4 patients in total, experiencing severe life-threatening orthostatic hypotension because of a novel cause. METHODS AND RESULTS: As in dopamine β-hydroxylase deficiency, concentrations of norepinephrine and epinephrine in the patients were low. Plasma dopamine β-hydroxylase activity, however, was normal, and the DBH gene had no mutations. Molecular genetic analysis was performed to determine the underlying genetic cause. Homozygosity mapping and exome and Sanger sequencing revealed pathogenic homozygous mutations in the gene encoding cytochrome b561 (CYB561); a missense variant c.262G>A, p.Gly88Arg in exon 3 in the Dutch family and a nonsense mutation (c.131G>A, p.Trp44*) in exon 2 in the American family. Expression of CYB561 was investigated using RNA from different human adult and fetal tissues, transcription of RNA into cDNA, and real-time quantitative polymerase chain reaction. The CYB561 gene was found to be expressed in many human tissues, in particular the brain. The CYB561 protein defect leads to a shortage of ascorbate inside the catecholamine secretory vesicles leading to a functional dopamine β-hydroxylase deficiency. The concentration of the catecholamines and downstream metabolites was measured in brain and adrenal tissue of 6 CYB561 knockout mice (reporter-tagged deletion allele [post-Cre], genetic background C57BL/6NTac). The concentration of norepinephrine and normetanephrine was decreased in whole-brain homogenates of the CYB561(-/-) mice compared with wild-type mice (P<0.01), and the concentration of normetanephrine and metanephrine was decreased in adrenal glands (P<0.01), recapitulating the clinical phenotype. The patients responded favorably to treatment with l-dihydroxyphenylserine, which can be converted directly to norepinephrine. CONCLUSIONS: This study is the first to implicate cytochrome b561 in disease by showing that pathogenic mutations in CYB561 cause an as yet unknown disease in neurotransmitter metabolism causing orthostatic hypotension.
Authors: Peilong Lu; Dan Ma; Chuangye Yan; Xinqi Gong; Mingjian Du; Yigong Shi Journal: Proc Natl Acad Sci U S A Date: 2014-01-21 Impact factor: 11.205
Authors: Wilhelmina H A de Jong; Kendon S Graham; Jan C van der Molen; Thera P Links; Michael R Morris; H Alec Ross; Elisabeth G E de Vries; Ido P Kema Journal: Clin Chem Date: 2007-09 Impact factor: 8.327
Authors: Stefan R Bornstein; Mayumi Yoshida-Hiroi; Sotiria Sotiriou; Mark Levine; Hans-Georg Hartwig; Robert L Nussbaum; Graeme Eisenhofer Journal: FASEB J Date: 2003-08-01 Impact factor: 5.191
Authors: J Deinum; G C H Steenbergen-Spanjers; M Jansen; F Boomsma; J W M Lenders; F J van Ittersum; N Hück; L P van den Heuvel; R A Wevers Journal: J Med Genet Date: 2004-04 Impact factor: 6.318
Authors: Kuixing Zhang; Dekker C Deacon; Fangwen Rao; Andrew J Schork; Maple M Fung; Jill Waalen; Nicholas J Schork; Caroline M Nievergelt; Neil C Chi; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2013-10-16 Impact factor: 24.094
Authors: Gautier Koscielny; Gagarine Yaikhom; Vivek Iyer; Terrence F Meehan; Hugh Morgan; Julian Atienza-Herrero; Andrew Blake; Chao-Kung Chen; Richard Easty; Armida Di Fenza; Tanja Fiegel; Mark Grifiths; Alan Horne; Natasha A Karp; Natalja Kurbatova; Jeremy C Mason; Peter Matthews; Darren J Oakley; Asfand Qazi; Jack Regnart; Ahmad Retha; Luis A Santos; Duncan J Sneddon; Jonathan Warren; Henrik Westerberg; Robert J Wilson; David G Melvin; Damian Smedley; Steve D M Brown; Paul Flicek; William C Skarnes; Ann-Marie Mallon; Helen Parkinson Journal: Nucleic Acids Res Date: 2013-11-04 Impact factor: 16.971
Authors: Cyndya A Shibao; Karen Joos; John A Phillips; Joy Cogan; John H Newman; Rizwan Hamid; Jens Meiler; John Capra; Jonathan Sheehan; Francesco Vetrini; Yaping Yang; Bonnie Black; André Diedrich; David Roberston; Italo Biaggioni Journal: Neurology Date: 2021-05-04 Impact factor: 11.800
Authors: Michael Eigenschink; Danylo Savran; Christoph P Zitterer; Sebastian Granitzer; Magdalena Fritz; David M Baron; Ernst W Müllner; Ulrich Salzer Journal: Front Physiol Date: 2021-12-06 Impact factor: 4.566
Authors: Cyndya A Shibao; Emily M Garland; Bonnie K Black; Christopher J Mathias; Maria B Grant; Allen W Root; David Robertson; Italo Biaggioni Journal: Neurology Date: 2019-12-10 Impact factor: 9.910
Authors: Tessa Wassenberg; Jaap Deinum; Frans J van Ittersum; Erik-Jan Kamsteeg; Maartje Pennings; Marcel M Verbeek; Ron A Wevers; Mirjam E van Albada; Ido P Kema; Jorie Versmissen; Ton van den Meiracker; Jacques W M Lenders; Leo Monnens; Michèl A Willemsen Journal: J Inherit Metab Dis Date: 2020-10-15 Impact factor: 4.982
Authors: Martijn van Faassen; Rainer Bischoff; Karin Eijkelenkamp; Wilhelmina H A de Jong; Claude P van der Ley; Ido P Kema Journal: Anal Chem Date: 2020-06-12 Impact factor: 6.986